Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kristopher Oldham

Nurse Practitioner, Psychiatric/Mental Health Winter Garden, FL Nurse Practitioner

NPI 1619357787 CMS profile 10986213

1223 Daniels Rd, Winter Garden, FL 34787

Open in the dashboard

General payments

$4,556

219 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kristopher Oldham of Winter Garden, FL is reported in the CMS Open Payments database as having received $4,556 across 219 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,274 102
2024 General $320 19
2023 General $976 57
2022 General $655 25
2021 General $331 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kristopher Oldham
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Kristopher Oldham were reported at $2,274. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Kristopher Oldham Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $331 $166 $54–$482 $132
2022 $655 $195 $66–$559 $149
2023 $976 $233 $82–$673 $160
2024 $320 $236 $84–$688 $164
2025 $2,274 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. ACADIA Pharmaceuticals Inc $945 39 payments
  2. Axsome Therapeutics, Inc. $700 24 payments
  3. Otsuka America Pharmaceutical, Inc. $696 32 payments
  4. Neurocrine Biosciences, Inc. $375 11 payments
  5. Teva Pharmaceuticals USA, Inc. $323 28 payments
  6. Alkermes, Inc. $281 12 payments
  7. Vanda Pharmaceuticals Inc. $225 13 payments
  8. Avanir Pharmaceuticals, Inc. $190 12 payments
  9. AbbVie, Inc. $185 12 payments
  10. Corium, Inc. $155 9 payments
  11. Other $482 27 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,556 219 payments
Products named General payments · program years 2021–2025
  1. NUPLAZID $755 34 payments
  2. Auvelity $680 23 payments
  3. REXULTI $381 14 payments
  4. INGREZZA $375 11 payments
  5. NUEDEXTA $289 17 payments
  6. LYBALVI Cns $281 12 payments
  7. Austedo XR $257 18 payments
  8. FANAPT $225 13 payments
  9. LYBALVI Cns $215 9 payments
  10. LYBALVI Cns $215 9 payments
  11. Other $1,856 102 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 42 drugs

Part D claims

2,728

Median for Nurse Practitioner: 389

Drug cost

$1,947,343

Median for Nurse Practitioner: $21,885

Branded share of claims

40.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nuedexta Dextromethorphan Hbr/Quinidine Brand 228 $326,922
Rexulti Brexpiprazole Brand 225 $323,417
Austedo Xr Deutetrabenazine Brand 14 $272,257
Auvelity Dextromethorphan Hbr/Bupropion Brand 240 $265,324
Nuplazid Pimavanserin Tartrate Brand 55 $254,357
Ingrezza Valbenazine Tosylate Brand 30 $237,959
Vraylar Cariprazine Hcl Brand 61 $103,820
Abilify Maintena Aripiprazole Brand 23 $62,577
Mounjaro Tirzepatide Brand 23 $34,826
Caplyta Lumateperone Tosylate Brand 18 $29,026

The 10 drugs with the highest cost, of 42 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$72,498

Medicare's payments for the services billed

Medicare patients

334

Average age 76

Services billed

1,054

191 women, 143 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 72%
Diabetes 63%
Alzheimer's or dementia 57%
Chronic kidney disease 53%
Heart failure 51%
Ischemic heart disease 49%
Arthritis 45%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUPLAZID
  • ACADIA Pharmaceuticals Inc $175
$175 55 —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $55
$55 14 —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $50
$50 225 —
Auvelity
  • Axsome Therapeutics, Inc. $25
$25 240 —
QUVIVIQ
  • IDORSIA PHARMACEUTICALS US INC $14
$14 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

219 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record